Emyria Secures Landmark Medibank Agreement to Expand PTSD Treatment Access

The latest announcement is out from Emyria Ltd ( (AU:EMD) ).

Emyria Limited has secured a landmark multi-year funding agreement with Medibank, Australia’s largest private health insurer, to support its Empax PTSD treatment program. This agreement marks a significant milestone as it is the first time a major insurer in Australia has reimbursed a psychotherapy-led PTSD treatment, enhancing accessibility to high-quality care. The company has also opened a second Empax clinic and reported strong clinical outcomes, with 63% of patients no longer meeting PTSD diagnostic criteria. Emyria’s strategic moves, including securing $4 million in funding, position it to expand its mental health solutions across Australia, addressing the growing mental health crisis and setting a precedent for future reimbursement partnerships.

More about Emyria Ltd

Emyria Limited is a leader in developing and delivering innovative mental health treatments, focusing on psychotherapy-led models for conditions such as PTSD and treatment-resistant depression. The company is known for its data-driven approach and is expanding its footprint in the mental health sector through strategic partnerships and funding agreements.

Average Trading Volume: 2,258,580

Technical Sentiment Signal: Hold

Current Market Cap: A$25.07M

For an in-depth examination of EMD stock, go to TipRanks’ Overview page.